Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer.

1500 Background: NSABP P-2 (STAR) was a randomized, double-blinded trial of tamoxifen vs raloxifene for the reduction of breast cancer incidence. The initial report from 2006 found raloxifene to be as effective as tamoxifen in preventing invasive breast cancer, but with fewer associated toxicities. In 2010 updated results indicated that raloxifene retained 76% of the effectiveness of tamoxifen in preventing invasive breast cancer and remained...